PDF(Pubmed)
Abstract：
Gamma delta (γδ) T cells demonstrate strong cytotoxicity against diverse cancer cell types in an MHC-independent manner, rendering them promising contenders for cancer therapy. Although amplification and adoptive transfer of γδ T cells are being evaluated in the clinic, their therapeutic efficacy remains unsatisfactory, primarily due to the influence of the immunosuppressive tumor microenvironment (TME). Currently, the utilization of targeted therapeutic antibodies against inhibitory immune checkpoint (ICP) molecules is a viable approach to counteract the immunosuppressive consequences of the TME. Notably, PD-1/PD-L1 checkpoint inhibitors are considered primary treatment options for diverse malignancies, with the objective of preserving the response of αβ T cells. However, γδ T cells also infiltrate various human cancers and are important participants in cancer immunity, thereby influencing patient prognosis. Hence, it is imperative to comprehend the reciprocal impact of the PD-1/PD-L1 axis on γδ T cells. This understanding can serve as a therapeutic foundation for improving γδ T cells adoptive transfer therapy and may offer a novel avenue for future combined immunotherapeutic approaches.
摘要：
γδ（γδ）T细胞以不依赖MHC的方式对多种癌细胞类型表现出强烈的细胞毒性，使他们成为癌症治疗的有希望的竞争者。尽管γδT细胞的扩增和过继转移正在临床中进行评估，它们的治疗效果仍然不令人满意，主要是由于免疫抑制肿瘤微环境（TME）的影响。目前,利用针对抑制性免疫检查点(ICP)分子的靶向治疗性抗体是抵消TME免疫抑制后果的可行方法.值得注意的是,PD-1/PD-L1检查点抑制剂被认为是各种恶性肿瘤的主要治疗选择。目的是保持αβT细胞的反应。然而,γδT细胞也渗透到各种人类癌症中，是癌症免疫的重要参与者，从而影响患者预后。因此，必须了解PD-1/PD-L1轴对γδT细胞的相互影响。这种理解可以作为改善γδT细胞过继转移疗法的治疗基础，并可能为未来的联合免疫治疗方法提供新的途径。
